Key result
ROCK2 inhibition reduces cardiac fibrosis and renal injury in hypertensive mice independent of blood pressure.
Why the study?
Adjunctive immune-modulating therapies are needed to protect hypertensive patients from end-organ damage despite achieving target blood pressure, due to unresolved inflammation involving T helper 17 cells and ROCK2.
Does ROCK2 inhibition via KD025/belumosudil or genetic deletion reduce hypertensive end-organ damage in a mouse model?
Does ROCK2 inhibition via KD025/belumosudil or genetic deletion reduce hypertensive end-organ damage in a mouse model?
Pharmacological inhibition of ROCK2 mitigates hypertensive end-organ damage independently of blood pressure lowering in mice, suggesting potential as an immune-modulating adjunctive therapy.
ROCK2 inhibition may limit hypertensive end-organ injury independently of BP in mice; leaves open translation to human therapy.
BACKGROUND: Despite achieving target blood pressure, hypertensive individuals have an elevated risk of cardiovascular disease, likely due to unresolved inflammation. Thus, adjunctive immune-modulating therapies are needed to protect patients with hypertension from end-organ damage. We previously showed that T helper 17 cells, which produce the proinflammatory cytokine IL (interleukin)-17A, contribute to hypertensive tissue injury. ROCK2 (Rho-associated coiled-coil–containing protein kinase 2) is a molecular switch governing T helper cell differentiation by promoting T helper 17 polarization and inhibiting T regulatory cell polarization. The present study tests whether T-cell–specific deletion of Rock2 or the Food and Drug Administration–approved ROCK2-specific inhibitor KD025/belumosudil protects against hypertension-associated end-organ damage. METHODS: T-cell–specific Rock2 knockout mice ( Rock2 fl/fl CD4 Cre+ ) and Rock2 fl/fl littermate controls were subjected to a 21-day deoxycorticosterone acetate–salt model of hypertension. In parallel, KD025/belumosudil treatment (50 mg/kg per day) starting after day 10 in wild-type mice was used to test the therapeutic potential of targeting ROCK2. Blood pressure, cardiac fibrosis, renal injury, and infiltration of immune cells were assessed. RESULTS: T-cell–specific Rock2 deletion in mice attenuated the hypertensive response in the deoxycorticosterone acetate–salt model and protected from cardiac and aortic fibrosis. KD025/belumosudil treatment did not reduce blood pressure but did decrease proinflammatory T helper 17 polarization in vivo and increased the cardiac regulatory T cells/T helper 17 ratio. Despite no blood pressure change, KD025 reduced cardiac and aortic fibrosis, improved echocardiographic and invasive hemodynamic indices, and attenuated albuminuria and renal T-cell infiltration. CONCLUSIONS: ROCK2 inhibition may serve as an adjunct immune-modulating therapy to mitigate the end-organ damage that occurs in the heart, vasculature, and kidney in hypertension.
No takes yet. Share an insight, caveat, or question.
Fehrenbach et al. (2026) studied Hypertension-associated end-organ damage. KD025/belumosudil or T-cell-specific Rock2 deletion vs. Littermate controls or untreated wild-type mice was evaluated on Blood pressure, cardiac fibrosis, renal injury, and infiltration of immune cells. In a mouse model of hypertension, ROCK2 inhibition via KD025/belumosudil or T-cell-specific deletion reduced cardiac and aortic fibrosis and attenuated renal injury despite no blood pressure change.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: